Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/17/2025 | $28.00 | Outperform | RBC Capital Mkts |
| 1/7/2025 | $33.00 | Buy | Citigroup |
| 10/16/2024 | Sector Outperform | Scotiabank | |
| 8/28/2024 | $15.00 | Buy | Jefferies |
| 1/22/2024 | $35.00 | Overweight | JP Morgan |
| 11/2/2023 | $20.00 | Buy | Mizuho |
| 4/21/2023 | $33.00 | Outperform | Robert W. Baird |
| 7/7/2022 | $21.00 | Buy | Chardan Capital Markets |
WATERTOWN, Mass., Sept. 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 140,600 shares of EyePoint common stock to eight new employees. The stock options were granted on September 15, 2025. The grants were approved by the Compensation Committee and made
WATERTOWN, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that company management will participate at the following upcoming conferences: Citi's 2025 BioPharma Back to School ConferenceForum: Fireside ChatDate: Tuesday, September 2, 2025Time: 2:30 p.m. ET Cantor Global Healthcare ConferenceForum: Fireside ChatDate: Wednesday, September 3, 2025Time: 2:45 p.m. ETMorgan Stanley 23rd Annual Global Healthcare Conference Forum: 1x1 Investor MeetingsDate: Tuesday, September 9, 2025 A live webcast an
WATERTOWN, Mass., Aug. 18, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 18,000 shares of EyePoint common stock to two new employees. The stock options were granted on August 15, 2025. The grants were approved by the Compensation Committee and made as an ind
RBC Capital Mkts initiated coverage of EyePoint Pharmaceuticals with a rating of Outperform and set a new price target of $28.00
Citigroup initiated coverage of EyePoint Pharmaceuticals with a rating of Buy and set a new price target of $33.00
Scotiabank initiated coverage of EyePoint Pharmaceuticals with a rating of Sector Outperform
S-8 - EyePoint Pharmaceuticals, Inc. (0001314102) (Filer)
10-Q - EyePoint Pharmaceuticals, Inc. (0001314102) (Filer)
8-K - EyePoint Pharmaceuticals, Inc. (0001314102) (Filer)
4 - EyePoint Pharmaceuticals, Inc. (0001314102) (Issuer)
4 - EyePoint Pharmaceuticals, Inc. (0001314102) (Issuer)
4 - EyePoint Pharmaceuticals, Inc. (0001314102) (Issuer)
4 - EyePoint Pharmaceuticals, Inc. (0001314102) (Issuer)
4 - EyePoint Pharmaceuticals, Inc. (0001314102) (Issuer)
4 - EyePoint Pharmaceuticals, Inc. (0001314102) (Issuer)
WATERTOWN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced the appointment of Reginald J. Sanders, M.D., FASRS, a distinguished leader in ophthalmology, to its Board of Directors. "I am pleased to welcome Dr. Sanders to EyePoint's Board," said Göran Ando, M.D., Chair of the Board of Directors of EyePoint. "Scientific and medical leadership underpin our mission to develop innovative therapeutics for patients with serious retinal diseases, and as a prominent leader in the retina community, Dr. San
WATERTOWN, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced the appointment of Fred Hassan, a distinguished industry leader to its Board of Directors. "I am honored to welcome Fred Hassan to EyePoint's Board," said Göran Ando, M.D., Chair of the Board of Directors of EyePoint Pharmaceuticals. "He joins at an important time for the Company as we approach first patient dosing for the pivotal Phase 3 LUGANO trial of DURAVYU™ in wet age-related macular degeneration (AMD) and as we prepare for future
- Charles Wykoff, M.D., Ph.D. joins Carl Regillo, M.D., FACS as co-chair of Scientific Advisory Board – - Usha Chakravarthy, M.B.B.S, PhD., Allen Ho, M.D. FACS FASRS and Frank Holz, M.D., F.E.B.O, F.A.R.V.O join in advance of global Phase 3 clinical trials for EYP-1901(DURAVYU) in wet AMD – - Company on track to initiate the first Phase 3 pivotal trial (LUGANO) for DURYVU in wet AMD in 2H 2024 - WATERTOWN, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced the appointment of leading global ophthalmologists
– Completed Phase 3 enrollment for DURAVYU™ in wet AMD with over 800 patients enrolled and randomized – – LUGANO and LUCIA trials each rapidly enrolled in seven months underscoring strong physician and patient interest – – Topline 56-week data for LUGANO on track for readout in mid-2026 with LUCIA topline data to closely follow – – Northbridge, MA commercial manufacturing facility on line with DURAVYU registration batches underway – – $256 million of cash, cash equivalents and marketable securities as of June 30, 2025, provides cash runway into 2027, beyond topline data for both Phase 3 wet AMD trials – WATERTOWN, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuti
WATERTOWN, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, August 6, 2025 to report its second quarter 2025 financial results and highlight recent corporate developments. To access the live conference call, please register using the audio conference link: https://register-conf.media-server.com/register/BI2f02d8b4966b40da83f2ef4135b2ba78. A live audio webcast of the event can be accessed via the Investors section of the
– Enrollment continues to exceed expectations in DURAVYU™ Phase 3 wet AMD clinical trials with over 90% of patients randomized into the LUGANO trial and over 50% into the LUCIA trial, reinforcing confidence in enrollment completion in 2H 2025 and expected first-to-market advantage – – $318 million of cash, cash equivalents and marketable securities as of March 31, 2025, provides cash runway into 2027, beyond topline data for both Phase 3 wet AMD trials expected in 2026 – WATERTOWN, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious
SC 13G/A - EyePoint Pharmaceuticals, Inc. (0001314102) (Subject)
SC 13G/A - EyePoint Pharmaceuticals, Inc. (0001314102) (Subject)
SC 13G/A - EyePoint Pharmaceuticals, Inc. (0001314102) (Subject)